首页 › 基金 › SUPERSTRING CAPITAL MANAGEMENT LP › URGN
SUPERSTRING CAPITAL MANAGEMENT LP 对 URGN 的持仓历史
UROGEN PHARMA LTD · 医疗保健
SUPERSTRING CAPITAL MANAGEMENT LP 在 Q2 2026 的 13F 申报中披露持有 URGN(UROGEN PHARMA LTD)191,313 股,市值约 US$7.0M,约占其申报组合的 4.45%,在其申报持仓中市值排名第 10 位。 SUPERSTRING CAPITAL MANAGEMENT LP 最近 11 个申报季度中有 9 个季度披露了 URGN 持仓,最早可追溯至 Q4 2023。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
SUPERSTRING CAPITAL MANAGEMENT LP 对 URGN 的持仓演变
SUPERSTRING CAPITAL MANAGEMENT LP 于 Q4 2023 首次披露 URGN 持仓:255,430 股(约 US$3.8M)。 该持仓在 Q4 2025 达到峰值 718,354 股,市值约 US$16.8M。 在 9 次申报中,SUPERSTRING CAPITAL MANAGEMENT LP 3 次增持、3 次减持、1 次保持不变。 最近一期申报(Q2 2026)显示持股 191,313 股、市值约 US$7.0M,环比减持 -196,058 股。。 持仓曾出现大幅变动:Q2 2025 减持约 79% (随后一个季度股价上涨 46%)、Q4 2025 增持约 717% (随后一个季度股价下跌 23%)、Q2 2026 减持约 51% (随后一个季度股价上涨 10%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2023 | 255.43K | $3.83M | 新进 |
| Q1 2024 | 288.27K | $4.32M | 增持 |
| Q4 2024 | 301.21K | $3.21M | 新进 |
| Q1 2025 | 423.63K | $4.69M | 增持 |
| Q2 2025 | 87.91K | $1.20M | 减持 |
| Q3 2025 | 87.91K | $1.75M | 持有 |
| Q4 2025 | 718.35K | $16.82M | 增持 |
| Q1 2026 | 387.37K | $6.96M | 减持 |
| Q2 2026 | 191.31K | $7.04M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 URGN 与 13F 数据
URGN(UROGEN PHARMA LTD)属于医疗保健行业。我们追踪的基金中还有 39 只申报持有 URGN,申报仓位最大的包括:RTW INVESTMENTS, LP (US$167.2M), Kynam Capital Management, LP (US$89.6M), Jefferies Financial Group Inc. (US$80.9M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 URGN 的基金
- RTW INVESTMENTS, LP 4.54M 股 · $167.22M · Q2 2026
- Kynam Capital Management, LP 2.43M 股 · $89.58M · Q2 2026
- Jefferies Financial Group Inc. 2.20M 股 · $80.95M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 1.67M 股 · $61.58M · Q2 2026
- Opaleye Management Inc. 1.44M 股 · $52.99M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 1.30M 股 · $47.91M · Q2 2026
- MPM BioImpact LLC 933.41K 股 · $34.35M · Q2 2026
- Soleus Capital Management, L.P. 829.81K 股 · $30.54M · Q2 2026
- Boxer Capital Management, LLC 500.00K 股 · $18.40M · Q2 2026
- Privium Fund Management B.V. 210.00K 股 · $7.73M · Q2 2026
更多关于 SUPERSTRING CAPITAL MANAGEMENT LP
常见问题
How long has SUPERSTRING CAPITAL MANAGEMENT LP held URGN?
SUPERSTRING CAPITAL MANAGEMENT LP has disclosed URGN holdings in 9 of the last 11 reported quarters, going back to Q4 2023.
What is SUPERSTRING CAPITAL MANAGEMENT LP's current position in URGN?
As of Q2 2026, SUPERSTRING CAPITAL MANAGEMENT LP holds 191.31K shares of URGN (UROGEN PHARMA LTD), valued at $7.04M, representing 4.45% of its reported portfolio and ranking #10.
Has SUPERSTRING CAPITAL MANAGEMENT LP been buying or selling URGN?
In the latest 13F filing (Q2 2026), SUPERSTRING CAPITAL MANAGEMENT LP reduced its position in URGN. The position peaked in Q4 2025 at 718.35K shares.
Which other funds hold URGN?
Other major institutional holders of URGN include RTW INVESTMENTS, LP, Kynam Capital Management, LP, Jefferies Financial Group Inc., among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.